Anpac Bio Surpasses 40,000 Case Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers.

SACRAMENTO, Calif., March 28, 2017 /PRNewswire/ — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 40,000 cases worldwide of the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.

Described as “game changing”, in World Nobel Prize Laureate Summit publications, Anpac Bio’s CDA medical devices and technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or “Blood Biopsies”, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.

Comprehensive research validity data from the 40,000 cases processed to date indicate Anpac Bio’s CDA diagnostics far exceed existing or competing technologies – revealing a sensitivity and specificity rate range of 75%-90% for over 16 different types of cancer – most at the disease’s earliest stages.

“Since our company launched in 2008, we have really pioneered the ‘liquid biopsy’ space,” states Dr. Yu. “Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in really great demand right now. We’ve processed over 40,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We’re very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives, by 2018!”

Anpac Bio maintains research and development, and manufacturing operations, in six sites worldwide, employing over 100 people. Filing over 150 CDA technology-related patent applications internationally to date, the company presented its latest research results, “Investigations of a novel diagnostic technology for colorectal cancer”, at the ASCO 2017 Gastrointestinal Cancers Symposium.

©2021 Anpac Bio-Medical Science Co., Ltd.